Compare DuPont de Nemours Inc (DD) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DuPont de Nemours Inc vs TG Therapeutics Inc — how do they compare? DuPont de Nemours Inc trades at $144.83 (market cap $19.51B), while TG Therapeutics Inc trades at $49.59 (market cap $7.64B). The key difference: DuPont de Nemours Inc is far larger — about 2.6× TG Therapeutics Inc's market cap, and DuPont de Nemours Inc pays a 1.66% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| DD | TGTX | |
|---|---|---|
Market Cap | $19.51B | $7.64B |
Sector | Basic Materials | Health |
52-Week High | $154.59 | $59.06 |
52-Week Low | $90.24 | $26.94 |
Enterprise Value | $20.90B | $7.84B |
Dividend Yield | 1.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DuPont (DD) trades at $143.64, up 1.47% today, with strong technical momentum as price approaches resistance near $146. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $1.88 exceeding the $1.76 estimate, and raised full-year 2026 guidance. Recent news highlights contract wins in water treatment and R&D innovation awards, though the stock faces valuation concerns with a P/E of 62 and negative net income in 2025.
The outlook is cautiously optimistic given earnings momentum and analyst bullishness (58% buy ratings), but high valuation and thin profit margins pose risks. The consensus price target of $232.80 suggests significant upside if execution continues, though investors should monitor debt levels and PFAS litigation developments that could impact financials.
TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.
Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
